3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
88
Gynecologic
3
Thoracic
2
Sarcoma
2
Head & Neck
2
Genitourinary
2
Breast
2
Conditions
Head and Neck Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
8
Nasopharyngeal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Salivary Gland Neoplasms
2
Recurrence
2
Osteosarcoma
2
Optic Nerve Glioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasm Metastasis
2
Melanoma
2
Familial ependymoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Astrocytoma
2
Wilms Tumor
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Teratoma
1
Spinocerebellar Degenerations
1
Interventions
pembrolizumab
20
Docetaxel
8
Carboplatin
8
Fluorouracil
6
Cisplatin
6
Nivolumab
5
fludarabine
4
Trastuzumab
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Cyclophosphamide
4
Biopsy
4
Bevacizumab
4
fludarabine phosphate
3
durvalumab
3
atezolizumab
3
Taxes
3
Radiotherapy
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
ulixertinib
2
tisotumab vedotin
2
spartalizumab
2
belinostat
2
adavosertib
2
X-Rays
2
Vorinostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Oxaliplatin
×
Head & Neck
×
Clear all
NCT05891171
2026-03-31
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled